Literature DB >> 7901259

The clinical efficacy of Rev-Eyes in reversing the effects of pupillary dilation.

C G Connor1, J B Campbell, W W Tirey.   

Abstract

BACKGROUND: Pupillary dilation to perform binocular indirect ophthalmoscopy has become a routine part of optometric practice. Many patients find the resulting photophobia and incapacity of near vision to be an inconvenience. Rev-Eyes (0.5% dapiprazole HCl) is a new alpha-antagonist reported to reverse the effects of pupillary dilation in approximately one hour. This study was designed to evaluate the usefulness of Rev-Eyes in a routine clinical setting.
METHODS: Seventy-nine subjects free of eye disease that ranged in age from 21 to 40 years received 0.5% proparacaine, 2.5% phenylephrine, and 1.0% tropicamide in each eye. Rev-Eyes was administered to 61 subjects. Eighteen control subjects received 5% NaCl. Effects on pupil diameter, accommodation, and distance and near visual acuity were measured. Conjunctival vasodilation, corneal stippling, patient comfort, and intraocular pressure (IOP) were also evaluated.
RESULTS: Our results confirm that a statistically significant reduction in pupil diameter is achieved 60 minutes after installation of Rev-Eyes. However, no significant improvement was obtained in any of the other functional aspects measured
CONCLUSIONS: Our data suggest limited utility for Rev-Eyes with a young population. The recovery rate of near visual acuity and amplitude of accommodation is identical with or without Rev-Eyes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7901259

Source DB:  PubMed          Journal:  J Am Optom Assoc        ISSN: 0003-0244


  1 in total

1.  Comparison of the effects on pupil size and accommodation of three regimens of topical dapiprazole.

Authors:  C S Wilcox; J F Heiser; A M Crowder; N J Wassom; B B Katz; J L Dale
Journal:  Br J Ophthalmol       Date:  1995-06       Impact factor: 4.638

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.